TruScreen offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and wellbeing of women around the world.
TruScreen’s world-class technology has the power to save lives
TruScreen is a cost-effective test that can be used outside existing laboratory infrastructure and has high potential to aid in reducing cervical cancer mortality.
TruScreen has been extensively evaluated in studies involving more than 10,000 women worldwide. In our most recent study, in Guadalajara, Mexico, TruScreen was found to be more than twice as sensitive as the Pap smear in identifying both low grade and high grade cervical lesions.
TruScreen’s sensitivity for high grade lesions was 93%.
Unlike the Pap test, tissue samples are not collected, which minimises discomfort for patients. This new technology detects pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. The system uses low levels of electricity and light to examine the cervix as a hand-held wand is gently moved over the surface of the cervix.